Peptide Library

In clinical trials

Hormones & metabolism

Efpeglenatide

Evidence

Clinical trials

Class

Long-acting GLP-1 receptor agonist

/

Efpeglenatide

KEY TAKEAWAY

Efpeglenatide is a once-weekly GLP-1 receptor agonist based on exendin-4. Efpeglenatide is not FDA-approved and has been tested in clinical trials.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Long-acting GLP-1 receptor agonist

Being studied for

Studied in type 2 diabetes and obesity

Key fact

Efpeglenatide is not FDA-approved and has been tested in clinical trials.

Route

Weekly subcutaneous injection in trials

Evidence strength

Clinical trials

What it is

What it is

Efpeglenatide is a once-weekly GLP-1 receptor agonist based on exendin-4.

How it works

How it works

It activates GLP-1 receptors, which raises insulin release when blood sugar is high, slows stomach emptying and reduces appetite.

Regulatory status

Regulatory status

Efpeglenatide is not FDA-approved and has been tested in clinical trials.

What it is used for

What it is used for

Studied in type 2 diabetes and obesity.

Side effects and risks

Side effects and risks

Nausea, vomiting and diarrhea were the most common effects in trials.

Citations

Citations

Efpeglenatide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo